Effects of 1-(4-dimethylaminobenzylidene)indene (syn. NSC 80087, 14M21, DABI) on inbred strains of mice.
D000284:Administration, Oral; D000814:Aniline Compounds / Q000494:pharmacology / Q000633:toxicity; D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D001593:Benzyl Compounds / Q000494:pharmacology / Q000633:toxicity; D002273:Carcinogens; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced; D005260:Female; D007192:Indenes / Q000494:pharmacology / Q000633:toxicity*; D008113:Liver Neoplasms / Q000139:chemically induced; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000517:prevention & control; D051379:Mice; D008806:Mice, Inbred AKR; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D008815:Mice, Inbred Strains; D009374:Neoplasms, Experimental / Q000139:chemically induced; D010051:Ovarian Neoplasms / Q000139:chemically induced; D012509:Sarcoma / Q000139:chemically induced; D012878:Skin Neoplasms / Q000139:chemically induced
D000814:Aniline Compounds; D000970:Antineoplastic Agents; D001593:Benzyl Compounds; D002273:Carcinogens; D007192:Indenes; C002201:DABI